11.25.25 -- Answering The Call To Develop Novel Drugs For Rare Diseases

Targeted Protein Degradation is a core drug discovery strategy. Evolving terminology, from ternary complex dynamics to AI-guided design, is essential for scientists to navigate this advancing field in 2025.

This presentation discusses the shift in pharmaceuticals from small-molecule drugs to protein biologics and the associated challenges, particularly the immunogenic response.

Learn how researchers optimized CHO cell culture to boost IgG1 titer to 5.8 g/L and improve viability, which cut development time from 14 days to 12 while enhancing productivity.

Assimilate how to accelerate ADC candidates from early discovery to clinical development, enhancing the success rate of translating preclinical discoveries into effective cancer treatments.

A healthcare manufacturer facing space constraints and regulatory pressures outsourced their stability storage needs to another company, resulting in reduced costs and focus on core competencies.

Combination therapies delivered directly to the lung by dry powder inhalants are an effective means of reducing patient burden. Read about case studies that illustrate the potential for improving care.

Finding alternative solvent approaches could allow for lower volumes of less toxic solvents, significantly improving both the environmental and human health implications of new drugs produced.